Literature DB >> 25128064

Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer.

Elaheh Gheybi1, Jafar Amani, Ali Hatef Salmanian, Farhad Mashayekhi, Samaneh Khodi.   

Abstract

Breast cancer is the most common cancer among women in the world. One of the approaches for diagnosis of breast cancer is detection of its tumor-associated markers. Mucin 1 (MUC1), a tumor-associated antigen, is a transmembrane glycoprotein expressed by normal epithelial cells and overexpressed by carcinomas of epithelial origin. Also, human epidermal growth factor receptor-2 (HER2/erbB-2) belongs to the one of four members of tyrosin kinase type 1 family in which overexpression of HER2 is associated with malignancy in breast cancer. This study was aimed to bioinformatics analysis and designing a recombinant chimeric protein containing MUC1 and HER2 antigens to express in prokaryotic host (Escherichia coli) as breast cancer diagnosis tools. The immunogenic sequences of MUC1 and HER2 were extracted and fused together by a linker. The chimeric construct was analyzed by bioinformatics softwares. The optimization and purification, evaluation of the expression of chimeric protein was performed using Western blotting, ELISA, and immunohistochemistry. The results showed that the chimeric construct was stable and immunogenic domains were exposed. The pET-28a vector containing chimeric gene had high level of protein expression. The recombinant chimeric protein was confirmed using Western blotting, and it was investigated using ELISA and IHC. Then, the MUC1 and HER2 combined peptides can be used as coating antigens in ELISA for detection of antibodies against MUC1 or HER2 in human serum.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25128064     DOI: 10.1007/s13277-014-2483-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  33 in total

Review 1.  The tumor macroenvironment and systemic regulation of breast cancer progression.

Authors:  Zafira Castaño; Kristin Tracy; Sandra S McAllister
Journal:  Int J Dev Biol       Date:  2011       Impact factor: 2.203

Review 2.  Current technologies for HER2 testing in breast cancer.

Authors:  C B Moelans; R A de Weger; E Van der Wall; P J van Diest
Journal:  Crit Rev Oncol Hematol       Date:  2011-01-26       Impact factor: 6.312

3.  Antitumor effect of double immunization of mice with mucin 1 and its coding DNA.

Authors:  Natalya Mushenkova; Ekaterina Moiseeva; Alexandra Chaadaeva; William Den Otter; Elena Svirshchevskaya
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

4.  Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells.

Authors:  Edward Pichinuk; Itai Benhar; Oded Jacobi; Michael Chalik; Lotem Weiss; Ravit Ziv; Carolyn Sympson; Amolkumar Karwa; Nechama I Smorodinsky; Daniel B Rubinstein; Daniel H Wreschner
Journal:  Cancer Res       Date:  2012-04-16       Impact factor: 12.701

Review 5.  Current molecular diagnostics of breast cancer and the potential incorporation of microRNA.

Authors:  Christine K Zoon; Elizabeth Q Starker; Arianne M Wilson; Michael R Emmert-Buck; Steven K Libutti; Michael A Tangrea
Journal:  Expert Rev Mol Diagn       Date:  2009-07       Impact factor: 5.225

6.  Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.

Authors:  Caroline Desmetz; Caroline Bascoul-Mollevi; Philippe Rochaix; Pierre-Jean Lamy; Andrew Kramar; Philippe Rouanet; Thierry Maudelonde; Alain Mangé; Jerome Solassol
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

7.  Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity.

Authors:  Vivian Goodell; James Waisman; Lupe G Salazar; Corazon de la Rosa; John Link; Andrew L Coveler; Jennifer S Childs; Patricia A Fintak; Doreen M Higgins; Mary L Disis
Journal:  Mol Cancer Ther       Date:  2008-03-04       Impact factor: 6.261

8.  Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.

Authors:  I Witzel; S Loibl; G von Minckwitz; H Eidtmann; T Fehm; F Khandan; S Schmatloch; M Hauschild; J Bischoff; P A Fasching; C Mau; C Schem; B Rack; I Meinhold-Heerlein; C Liedtke; T Karn; J Huober; C Zu Eulenburg; Y Issa-Nummer; M Untch; V Müller
Journal:  Br J Cancer       Date:  2012-08-14       Impact factor: 7.640

9.  Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

Authors:  Vasso Apostolopoulos; Geoffrey A Pietersz; Anastasios Tsibanis; Annivas Tsikkinis; Heleni Drakaki; Bruce E Loveland; Sara J Piddlesden; Magdalena Plebanski; Dodie S Pouniotis; Michael N Alexis; Ian F McKenzie; Stamatis Vassilaros
Journal:  Breast Cancer Res       Date:  2006-06-15       Impact factor: 6.466

10.  Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1).

Authors:  Marina Isla Larrain; Sandra Demichelis; Marina Crespo; Ezequiel Lacunza; Alberto Barbera; Aldo Cretón; Francisco Terrier; Amada Segal-Eiras; María Virginia Croce
Journal:  J Exp Clin Cancer Res       Date:  2009-08-28
View more
  5 in total

Review 1.  Genetically modified proteins: functional improvement and chimeragenesis.

Authors:  Larissa Balabanova; Vasily Golotin; Anna Podvolotskaya; Valery Rasskazov
Journal:  Bioengineered       Date:  2015-07-25       Impact factor: 3.269

Review 2.  Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.

Authors:  Zahra Rashidijahanabad; Xuefei Huang
Journal:  Semin Immunol       Date:  2020-01-22       Impact factor: 11.130

3.  Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

Authors:  Jun Wang; Zhi Peng Gao; Song Qin; Chang Bai Liu; Li Li Zou
Journal:  Exp Ther Med       Date:  2017-08-22       Impact factor: 2.447

4.  Presentation of underglycosylated mucin 1 in pancreatic adenocarcinoma (PDAC) at early stages.

Authors:  Su-Tang Lo; Pamela Pantazopouos; Zdravka Medarova; Anna Moore
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

5.  Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice.

Authors:  Elaheh Gheybi; Ali Hatef Salmanian; Abbas Ali Imani Fooladi; Jafar Salimian; Hamideh Mahmoodzadeh Hosseini; Raheleh Halabian; Jafar Amani
Journal:  Iran J Basic Med Sci       Date:  2018-01       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.